Your browser doesn't support javascript.
loading
Latency Trend Analysis as a Guide to Screening Malignancy Survivors for Second Primary Thyroid Cancer.
Hussein, Mohammad; Mueller, Lauren; Issa, Peter P; Haidari, Muhib; Trinh, Lily; Toraih, Eman; Kandil, Emad.
Afiliación
  • Hussein M; Department of Surgery, School of Medicine, Tulane University, New Orleans, LA 70112, USA.
  • Mueller L; School of Medicine, Tulane University, New Orleans, LA 70112, USA.
  • Issa PP; School of Medicine, Louisiana State University Health Sciences Center, New Orleans, LA 70112, USA.
  • Haidari M; School of Medicine, Tulane University, New Orleans, LA 70112, USA.
  • Trinh L; School of Medicine, Tulane University, New Orleans, LA 70112, USA.
  • Toraih E; Division of Thyroid and Parathyroid Endocrine Surgery, Department of Otolaryngology-Head and Neck Surgery, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, MA 02114, USA.
  • Kandil E; Department of Surgery, School of Medicine, Tulane University, New Orleans, LA 70112, USA.
Biomedicines ; 10(8)2022 Aug 16.
Article en En | MEDLINE | ID: mdl-36009531
Primary cancer survivors have a higher risk of developing second primary thyroid cancer (SPTC). Patients with SPTC who survived primary malignancies, diagnosed from 1975 to 2016, were identified from the Surveillance, Epidemiology, and End Results (SEER) database (SEER 18 Registry). A total of 33,551 cancer cases were enrolled in the final analysis. Individuals with a primary malignancy were at a significant 90% increased risk of developing SPTC (SIR = 1.90, 95%CI = 1.86−1.93, p < 0.05) compared to the general population. More than half (54.7%) of SPTC diagnoses were made in the first three years after primary cancer diagnosis, and the most aggressive presentations of SPTC occurred within the first year following malignancy. A latency trend analysis identified persistent high risk for development of SPTC after diagnosis of lymphoma, leukemia, soft tissue tumors, kidney, breast, and uterine cancer; elevated 10-year risk for most cancers such as salivary gland, melanoma, stomach, lung, colon, ovarian, pancreas, prostate, and bladder; and high 5-year risk after cancers such as larynx, oral, orbit, bone, small intestine, and liver. Our latency period model identifying risk according to each type of primary cancer may aid clinicians in identifying at-risk patients to be screened for thyroid cancer and guide them in developing a surveillance plan according to the latency period attributed to a patient's primary cancer.
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Diagnostic_studies / Screening_studies Idioma: En Revista: Biomedicines Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Suiza
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Diagnostic_studies / Screening_studies Idioma: En Revista: Biomedicines Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Suiza